Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.59 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.57 |
| ▸ | NPC1 | O15118 | 2/20 | 0.53 |
| ▸ | RAB9A | P51151 | 2/20 | 0.53 |
| ▸ | PLAU | P00749 | 2/20 | 0.52 |
| ▸ | F12 | P00748 | 1/20 | 0.52 |
| ▸ | NCF1 | P14598 | 1/20 | 0.52 |
| ▸ | NOS3 | P29474 | 1/20 | 0.52 |
| ▸ | NOS1 | P29475 | 1/20 | 0.52 |
| ▸ | NOS2 | P35228 | 1/20 | 0.52 |
| ▸ | BACE1 | P56817 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 3/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.51 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | PLG | P00747 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31732807 | 1.00 | LMNA (0.59) | LMNACYP2A6NPC1RAB9APLAU | |
| Iodide SCHEMBL10722209 | 0.98 | LMNA (0.58) | LMNACYP2A6NPC1RAB9APLAU | |
| SCHEMBL27222070 | 0.86 | LMNA (0.54) | LMNACYP2A6NPC1RAB9APLAU | |
| SCHEMBL6748371 | 0.86 | LMNA (0.54) | LMNACYP2A6NPC1RAB9APLAU | |
| SCHEMBL27604309 | 0.86 | LMNA (0.54) | LMNACYP2A6NPC1RAB9APLAU | |
| SCHEMBL19099919 | 0.86 | LMNA (0.54) | LMNACYP2A6NPC1RAB9APLAU | |
| SCHEMBL6638130 | 0.86 | LMNA (0.54) | LMNACYP2A6NPC1RAB9APLAU | |
| SCHEMBL6246973 | 0.86 | LMNA (0.54) | LMNACYP2A6NPC1RAB9APLAU | |
| SCHEMBL4265753 | 0.86 | LMNA (0.64) | LMNACYP2A6NPC1RAB9APLAU | |
| SCHEMBL3983719 | 0.86 | LMNA (0.54) | LMNACYP2A6NPC1RAB9APLAU |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 521 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-62221671-A | — | — | None | — | — | JP | disclosed |
| WO-2025237291-A1 | PREPARATION METHOD FOR ISOPROPYLISOQUINOLINE COMPOUND AND INTERMEDIATE THEREOF | 上海翰森生物医药科技有限公司 | 2025-11-20 | — | — | WO | disclosed |
| CN-116283759-B | Preparation method of 2-monofluoromethylquinoline and derivatives thereof | 济南大学 | 2025-02-28 | — | — | CN | disclosed |
| US-20240299387-A1 | HETEROCYCLIC EGFR INHIBITORS FOR USE IN THE TREATMENT OF CANCER | BLUEPRINT MEDICINES CORPORATION | 2024-09-12 | — | — | US | disclosed |
| US-20240239811-A1 | 5-(5-(PIPERIDIN-4-YL)THIENO[3,2-C]PYRAZOL-2-YL]INDAZOLE DERIVATIVES AND RELATED COMPOUNDS AS MODULATORS FOR SPLICING NUCLEIC ACIDS AND FOR THE T | REMIX THERAPEUTICS INC. | 2024-07-18 | — | — | US | disclosed |
| US-20240208967-A1 | Pyrimidine or Pyridine Compounds, Preparation Method Therefor and Pharmaceutical Uses Thereof | INVENTISBIO CO LTD (CN) | 2024-06-27 | — | — | US | disclosed |
| EP-4328230-A2 | AMINO ACID COMPOUNDS AND METHODS OF USE | Pliant Therapeutics, Inc. (US) | 2024-02-28 | — | — | EP | disclosed |
| US-20240025919-A1 | AZA-TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF | GENENTECH, INC. | 2024-01-25 | — | — | US | disclosed |
| US-20240025919-A1 | AZA-TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF | GENENTECH, INC. | 2024-01-25 | — | — | US | disclosed |
| US-20240025918-A1 | KRAS G12D Inhibitors | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2024-01-25 | — | — | US | disclosed |
| WO-2006007700-A1 | HEPATITIS C INHIBITOR DIPEPTIDE ANALOGS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-01-26 | — | — | WO | disclosed |
| WO-2006000085-A1 | HEPATITIS C INHIBITOR PEPTIDE ANALOGS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-01-05 | — | — | WO | disclosed |
| EP-0152082-B1 | AN ORGANIC SEMICONDUCTOR ELECTROLYTE CAPACITOR AND PROCESS FOR PRODUCING THE SAME | NIPPON CHEMI-CON CORPORATION (JP) | 1989-05-03 | — | — | EP | disclosed |
| US-4735823-A | ELECTROLYTE IS MIXTURE OF ISOPROPYLQUINOLIDIUM TETRACYANOQUINODIMETHANE COMPLEX AND A LACTONE | NIPPON CHEMI-CON CORPORATION (JP) | 1988-04-05 | — | — | US | disclosed |
| JP-S62221671-A | COMPLEX COMPOSITION FOR CAPACITOR | NIPPON CHEMICON CORP | 1987-09-29 | — | — | JP | disclosed |
| EP-0236842-A2 | Fusible electrically conductive mixtures | BAYER AG (DE) | 1987-09-16 | — | — | EP | disclosed |
| US-4656560-A | MIXTURE OF ISOPROPYLISOQUINOLINIUM TETRACYANOQUINODIMETHANE COMPLEX WITH A LACTONE | NIPPON CHEMI-CON CORPORATION (JP) | 1987-04-07 | — | — | US | disclosed |
| EP-0152082-A2 | An organic semiconductor electrolyte capacitor and process for producing the same | NIPPON CHEMI-CON CORPORATION (JP) | 1985-08-21 | — | — | EP | disclosed |
| US-4337256-A | ANTIINFLAMMATORY AGENTS; ANTIAGGLOMERANTS; ENZYME INHIBITORS; ANTIULCER AGENTS | TEIKOKU HORMONE MANUFACTURING CO., LTD. (JP) | 1982-06-29 | — | — | US | disclosed |
| EP-0013411-A1 | Isoquinoline derivatives, process for their preparation and pharmaceutical compositions containing them | TEIKOKU HORMONE MFG. CO., LTD. (JP) | 1980-07-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240299387-A1 | HETEROCYCLIC EGFR INHIBITORS FOR USE IN THE TREATMENT OF CANCER | EGFR, ERBB2, ERBB4 | LMNA 4828/4885CYP2A6 2456/4885NPC1 2065/4885 |
| US-20240208967-A1 | Pyrimidine or Pyridine Compounds, Preparation Method Therefor and Pharmaceutical Uses Thereof | EGFR, WEE1, DPYD | LMNA 3155/4885CYP2A6 213/4885NPC1 3163/4885 |
| US-20240025919-A1 | AZA-TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF | AZI2, TET3, OXA1L | LMNA 4245/4885CYP2A6 1444/4885NPC1 3948/4885 |
| US-20240239811-A1 | 5-(5-(PIPERIDIN-4-YL)THIENO[3,2-C]PYRAZOL-2-YL]INDAZOLE DERIVATIVES AND RELATED COMPOUNDS AS MODULATORS FOR SPLICING NUCLEIC ACIDS AND FOR THE T | HNRNPAB, HNRNPC, HNRNPA1 | LMNA 430/4885CYP2A6 4314/4885NPC1 459/4885 |
| US-20240025918-A1 | KRAS G12D Inhibitors | KRAS, NRAS, HRAS | LMNA 2462/4885CYP2A6 3433/4885NPC1 3197/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.